Cargando…

Germline TP53 mutational spectrum in French Canadians with breast cancer

BACKGROUND: Specific germline mutations in the hereditary breast-ovarian cancer susceptibility (HBC/HBOC) genes, BRCA1, BRCA2 and PALB2, have been shown to recur in French Canadians of Quebec, Canada, and this has been attributed to common ancestors. Germline TP53 mutation carriers are known to segr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arcand, Suzanna L, Akbari, Mohammed R, Mes-Masson, Anne-Marie, Provencher, Diane, Foulkes, William D, Narod, Steven A, Tonin, Patricia N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436120/ https://www.ncbi.nlm.nih.gov/pubmed/25925845 http://dx.doi.org/10.1186/s12881-015-0169-y

Ejemplares similares

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
por: Oros, Kathleen K, et al.
Publicado: (2006)

Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent
por: Tischkowitz, Marc, et al.
Publicado: (2013)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

RAD51C germline mutations in breast and ovarian cancer patients
por: Akbari, Mohammad R, et al.
Publicado: (2010)

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease
por: Fleury, Hubert, et al.
Publicado: (2015)

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene
por: Fierheller, Caitlin T., et al.
Publicado: (2021)

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
por: Birch, Ashley H., et al.
Publicado: (2011)

Germline mutation in the TP53 gene in uveal melanoma
por: Hajkova, Nikola, et al.
Publicado: (2018)

Characterization of three new serous epithelial ovarian cancer cell lines
por: Ouellet, Véronique, et al.
Publicado: (2008)

Germline TP53 mutations in Finnish breast cancer patients
por: Rapakko, K, et al.
Publicado: (2000)

Number of rare germline CNVs and TP53 mutation types
por: Silva, Amanda G, et al.
Publicado: (2012)

Clinical implications of germline mutations in breast cancer: TP53
por: Schon, Katherine, et al.
Publicado: (2017)

The chemiluminescence based Ziplex(® )automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip(® )expression profiles
por: Quinn, Michael CJ, et al.
Publicado: (2009)

Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors
por: Aceto, Gitana Maria, et al.
Publicado: (2019)

Identification of a novel CHEK2 variant and assessment of its contribution to the risk of breast cancer in French Canadian women
por: Novak, David J, et al.
Publicado: (2008)

Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
por: Köbel, Martin, et al.
Publicado: (2016)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Choroid Plexus Carcinomas With TP53 Germline Mutations: Management and Outcome
por: Li, Yanong, et al.
Publicado: (2021)

Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis
por: Kratz, Christian P., et al.
Publicado: (2021)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, David M, et al.
Publicado: (2012)

Inherited and de novo germline TP53 mutations in adult-onset sarcoma
por: Thomas, DM, et al.
Publicado: (2012)

Modeling the prevalent germline TP53 R337H mutation in mouse
por: Park, Ji-Hoon, et al.
Publicado: (2019)

Emerging insights into ethnic-specific TP53 germline variants
por: Fischer, Nicholas W, et al.
Publicado: (2023)

Increased Oxidative Damage in Carriers of the Germline TP53 p.R337H Mutation
por: Macedo, Gabriel S., et al.
Publicado: (2012)

Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women
por: Foulkes, William D, et al.
Publicado: (2007)

Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer
por: Elkholi, Islam E., et al.
Publicado: (2021)

An essential role for Ran GTPase in epithelial ovarian cancer cell survival
por: Barrès, Véronique, et al.
Publicado: (2010)

Germline TP53 Mutation and Clinical Characteristics of Korean Patients With Li-Fraumeni Syndrome
por: Park, Kyoung-Jin, et al.
Publicado: (2016)

Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
por: Kwong, Ava, et al.
Publicado: (2020)

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
por: Létourneau, Isabelle J, et al.
Publicado: (2012)

Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

Somatic TP53 variants frequently confound germline testing results
por: Weitzel, Jeffrey N., et al.
Publicado: (2017)

Germline TP53 Testing in Breast Cancers: Why, When and How?
por: Evans, D. Gareth, et al.
Publicado: (2020)

Effects of MDM2, MDM4 and TP53 Codon 72 Polymorphisms on Cancer Risk in a Cohort Study of Carriers of TP53 Germline Mutations
por: Fang, Shenying, et al.
Publicado: (2010)

Association of the germline TP53 R337H mutation with breast cancer in southern Brazil
por: Assumpção, Juliana G, et al.
Publicado: (2011)

Association of the germline TP53 R337H mutation with breast cancer in southern Brazil
por: Assumpção, Juliana G, et al.
Publicado: (2008)

High Frequency of Germline TP53 Mutations in a Prospective Adult-Onset Sarcoma Cohort
por: Mitchell, Gillian, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o742vphmolcqsmomcg4nks8jq4